1、北京XX医疗科技有限公司为广大癌症患者提供安全有效的治疗方案：CAR-T用于晚期癌症治疗的CAR-T疗法:CAR-T therapy for late-stage cancers:白血病 Leukemia淋巴瘤 Lymphoma肺癌 Lung cancer肝癌 Hepatocellular carcinoma胰腺癌 Pancreatic cancer胶质瘤 Glioma/Neuroblastoma产品/服务 Products/Service FDA:Break Through Therapy 革命性的应答率 Revolutionary response rate未来的癌症治疗终极策略：CAR-2、TFuture cure to cancer:Chimeric Antigen Receptor-T cellPBMC collectionT cell isolationActivationCAR infectionQCInjection1 Leukemia.2009.23,912918.2 Lancet.2015 Feb 7;385(9967):517-28.最畅销的抗癌药物 1Best anti-cancer medicineCAR-T 2需求：填补市场空白 Market vacancy90%2.7%复发白血病治疗的完全缓解率 Remission rate of refractory l3、eukemia1:专利申请号(Patent No.)201380010725.2 2:专利申请号(Patent No.)201280027682.412对癌细胞的杀伤率比友商高1倍以上Killing rate of cancer cells doubles competitors市值：31 亿美元Market Value:$3.1 billion市值：2561 亿美元Market Value:$256.1 billionXXImmunochinaApoptosis rate of cancer cellsNorvatis对白血病小鼠具有显著疗效Remarkable efficacy on le4、ukemic miceParalysis rate(%)Overall survival(%)DayDay对淋巴癌小鼠具有显著疗效Remarkable efficacy on lymphoma-bearing miceTumor volume(mm3)Overall survival(%)DayDay指标 index国外某著名药企 overseas competitorXXImmunochina细胞存活 viability70%95%CD8阳性率 EXP rate80%90%转导效率 efficiency20%30%内毒素含量 endotoxin3.5EU/mL0.01EU/mL真菌含量 fu5、ngus阴性阴性HIV-1 p2410pg/mL5pg/mLVSV-G DNA阴性阴性BSA1ug/mL0.1ug/mL领先的安全性和稳定性评价体系Leading evaluation system of safety and stability商业模式 Business model中心实验室 Central lab三甲医院 Class A hospital小医院小医院三甲医院Class A hospital小医院小医院三甲医院Class A hospital小医院小医院与顶尖医院长期合作Cooperate with top-class hospitals in the long run直接向6、医院收费Directly charge hospitals优质低价Provide high quality service at a reasonable price慈善医疗Charity treatmentQ3/2015Q4/2015Q1/2016Q2/2016提交8项专利Submission of 8 patents新适应症的细胞实验Cell experiments of new CARs启动单中心临床试验Initiation of clinical trial启动多中心临床试验Initiation of multicenter clinical trial新适应症的临床前试验Pre-cl7、inical studies on new CARs启动新适应症临床试验Initiation of clinical trials on new CARs拓展10家优质合作医院10 hospitals完成临床试验Finish 1st clinical trial开展收费服务Commercialization时间表 Timetable亮点 HighlightsCAR-T疗法是恶性肿瘤治疗的重大突破CAR-T therapy is a breakthrough in treating malignant tumors.CAR-T疗法是难治/复发白血病患者的希望CAR-T therapy is th8、e hope for leukemic patients.领先的CAR-T制备技术（对癌细胞杀伤率比友商高1倍以上）Leading technology of CAR-T(killing rate of cancer cells doubles the competitors)多种临床前模型验证疗效Proven efficacy by various pre-clinical models完备的质量控制体系Complete QC system合伙人：清华博士+临床医生Partners:Ph.D.from Tsinghua Univ.&clinician行业经验：I类抗癌新药研发、III类医疗器械研发Expertise:R&D of anti-cancer medicine and medical equipment学术背景：癌症生物学、分子生物学、临床医学Academic:cancer biology,molecular biology and clinical medicine创新能力：2015年内提交9项专利Innovation:9 patents in 2015团队 TeamEvery cloud has a silver lining.